ES2155821T3 - Toxinas quimericas mejoradas. - Google Patents

Toxinas quimericas mejoradas.

Info

Publication number
ES2155821T3
ES2155821T3 ES91906038T ES91906038T ES2155821T3 ES 2155821 T3 ES2155821 T3 ES 2155821T3 ES 91906038 T ES91906038 T ES 91906038T ES 91906038 T ES91906038 T ES 91906038T ES 2155821 T3 ES2155821 T3 ES 2155821T3
Authority
ES
Spain
Prior art keywords
fragment
dominant
difteria
toxin
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91906038T
Other languages
English (en)
Other versions
ES2155821T5 (es
Inventor
Diane Williams
John R Murphy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Medical Center
Original Assignee
Boston Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27049417&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2155821(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boston Medical Center filed Critical Boston Medical Center
Publication of ES2155821T3 publication Critical patent/ES2155821T3/es
Application granted granted Critical
Publication of ES2155821T5 publication Critical patent/ES2155821T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Detergent Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

SE PRESENTA UNA TOXINA QUIMERICA QUE COMPRENDE FRAGMENTOS DE PROTEINA UNIDOS MEDIANTE ENLACE PEPTIDOS, LA TOXINA QUIMERICA COMPRENDE, EN ORDEN SECUENCIAL, COMENZANDO POR EL EXTREMO DEL TERMINAL AMINO DE LA TOXINA QUIMERICA, (A) UN FRAGMENTO A ENZIMATICAMENTE ACTIVO DE TOXINA DE LA DIFTERIA, (B) UN PRIMER FRAGMENTO QUE INCLUYE EL DOMINANTE DE UNION 1 SUB 1 ADYACENTE AL FRAGMENTO A DE LA TOXINA DE LA DIFTERIA, (C) UN SEGUNDO FRAGMENTO QUE COMPRENDE AL MENOS UNA PARTE DE LA ZONA DE LA TRANSMEMBRANA HIDROFOBICA DEL FRAGMENTO B DE LA TOXINA DE LA DIFTERIA, UN SEGUNDO FRAGMENTO QUE TIENE AL MENOS UNA ELIMINACION DE AL MENOS 50 RESIDUOS AMINOACIDOS DE LA TOXINA DE LA DIFTERIA, LA ELIMINACION SERA DESDE EL TERMINAL C HASTA LA PARTE DE LA ZONA DE LA TRANSMEMBRANA, Y EL SEGUNDO FRAGMENTO NO INCLUYE EL DOMINANTE 1 SUB 2 Y, (D) UN TERCER FRAGMENTO QUE COMPRENDE UNA PARTE DEL LIGANTE POLIPEPTIDO ESPECIFICO DE LA CELULA, LA PARTE INCLUYE AL MENOS UNA PARTE DEL DOMINANTE DE UNION DEL LIGANTE POLIPEPTIDO,LA PARTE DEL DOMINANTE DE UNION ES EFECTIVA PARA PROVOCAR QUE LA TOXINA QUIMERICA SE UNA SELECTIVAMENTE A UNA CLASE PREDETERMINADA DE CELULAS QUE SON ATACADAS POR EL FRAGMENTO A ENZIMATICO ACTIVO.
ES91906038T 1990-03-02 1991-02-28 Toxinas quimericas mejoradas. Expired - Lifetime ES2155821T5 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US48860890A 1990-03-02 1990-03-02
US488608 1990-03-02
US53743090A 1990-06-13 1990-06-13
US537430 1990-06-13

Publications (2)

Publication Number Publication Date
ES2155821T3 true ES2155821T3 (es) 2001-06-01
ES2155821T5 ES2155821T5 (es) 2008-04-16

Family

ID=27049417

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91906038T Expired - Lifetime ES2155821T5 (es) 1990-03-02 1991-02-28 Toxinas quimericas mejoradas.

Country Status (11)

Country Link
US (6) US5616482A (es)
EP (1) EP0517829B2 (es)
JP (1) JP3311346B2 (es)
AT (1) ATE200493T1 (es)
CA (1) CA2076678C (es)
DE (1) DE69132581T3 (es)
DK (1) DK0517829T4 (es)
ES (1) ES2155821T5 (es)
FI (1) FI923915A7 (es)
GR (1) GR3036081T3 (es)
WO (1) WO1991013090A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214787B1 (en) * 1993-09-21 2007-05-08 United States Of America As Represented By The Secretary Of The Army Recombinant vaccine against botulinum neurotoxin
US6737511B1 (en) 1999-08-16 2004-05-18 The United States Of America As Represented By The Department Of Health And Human Services Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis
US20030162733A1 (en) * 2000-11-27 2003-08-28 Haynes Joel R. Nucleic acid adjuvants
US7273722B2 (en) * 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
US7585942B2 (en) * 2003-11-25 2009-09-08 Anjin Corporation Diphtheria toxin variant
RU2006138235A (ru) * 2004-03-31 2008-05-10 Трофоджен, Инк. (Us) Суперагонисты человеческих гликопротеиновых гормонов и способы их применения
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
ZA200901365B (en) * 2006-08-28 2010-05-26 Clinuvel Pharmaceuticals Ltd Method for reducing incidence or rate of development of skin cancers and related conditions
EP3207941B3 (en) 2006-09-07 2020-08-19 Scott & White Memorial Hospital Methods and compositions based on diphtheria toxin-interleukin-3 conjugates
US20090010966A1 (en) * 2007-06-21 2009-01-08 Angelica Therapeutics, Inc. Modified diphtheria toxins
EP2268297A4 (en) * 2008-02-29 2011-11-16 Angelica Therapeutics Inc MODIFIED TOXINS
US9321820B2 (en) * 2009-10-14 2016-04-26 The Regents Of The University Of Colorado Compositions and methods for treating bladder cancer
EP2968450A4 (en) 2013-03-15 2016-10-26 Angelica Therapeutics Inc MODIFIED TOXINS
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11203626B2 (en) 2016-03-10 2021-12-21 The Johns Hopkins University Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
MX2018010850A (es) 2016-03-10 2019-05-15 Univ Johns Hopkins Métodos para producir proteínas de fusión de toxina diftérica monoméricas y libres de agregados y usos terapéuticos.
US11965009B2 (en) 2016-03-10 2024-04-23 The Johns Hopkins University Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2022043863A1 (en) 2020-08-26 2022-03-03 Citius Pharmaceuticals, Inc. Combination for use in methods of treating cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE25197T1 (de) * 1982-05-12 1987-02-15 Harvard College Hybridproteinekodierende fusionierte gene, sie enthaltende klonierungsvektoren und deren verwendung.
US4468382A (en) † 1982-07-15 1984-08-28 New England Medical Center, Inc. Polypeptide-toxin hybrid protein
EP0335476A3 (en) * 1984-02-08 1989-12-13 Cetus Corporation Recombinant methods for the production of ricin a, ricin b, ricin or diphtheria toxin (dt)a or ab' fragment, suitable hosts and vectors therefor, and conjugates comprising ricin toxin a chain or diphtheria toxin
US4830962A (en) * 1984-02-09 1989-05-16 Cetus Corporation Recombinant diphtheria toxin fragments
NZ212312A (en) * 1984-06-07 1988-09-29 John Richard Murphy Hybrid protein comprising fragments of diphtheria toxin and part of cell-specific ligand; and fused gene therefor
EP0246307B1 (en) * 1985-11-13 1994-02-02 University Hospital The Cys codon-modified dna
IN165717B (es) * 1986-08-07 1989-12-23 Battelle Memorial Institute
IL89504A0 (en) * 1988-03-08 1989-09-10 Univ Wyoming Diphtheria toxin derivative,process for the preparation thereof and pharmaceutical composition containing the same
WO1991019745A1 (en) * 1990-06-13 1991-12-26 The University Hospital Chimeric toxins with improved inter-domain geometry

Also Published As

Publication number Publication date
FI923915A0 (fi) 1992-09-01
AU7493191A (en) 1991-09-18
JP3311346B2 (ja) 2002-08-05
FI923915L (fi) 1992-09-01
US5616482A (en) 1997-04-01
DK0517829T3 (da) 2001-05-07
US5932471A (en) 1999-08-03
DE69132581T3 (de) 2008-07-17
FI923915A7 (fi) 1992-09-01
GR3036081T3 (en) 2001-09-28
DE69132581T2 (de) 2002-04-11
DE69132581D1 (de) 2001-05-17
EP0517829B1 (en) 2001-04-11
EP0517829B2 (en) 2007-12-26
US5763250A (en) 1998-06-09
WO1991013090A1 (en) 1991-09-05
ES2155821T5 (es) 2008-04-16
US5703039A (en) 1997-12-30
DK0517829T4 (da) 2008-03-03
CA2076678C (en) 1999-09-28
CA2076678A1 (en) 1991-09-03
US5863891A (en) 1999-01-26
ATE200493T1 (de) 2001-04-15
JPH06500531A (ja) 1994-01-20
US5677148A (en) 1997-10-14
AU661819B2 (en) 1995-08-10
EP0517829A1 (en) 1992-12-16
EP0517829A4 (en) 1993-05-05

Similar Documents

Publication Publication Date Title
AU573529B2 (en) Hybrid proteins
ATE408699T1 (de) Verabreichung von nukleinsäuren und proteinen an zellen
DK1265914T3 (da) WNT-1-relaterede polypeptider og nukleinsyrer, der koder for samme
AU676859B2 (en) Synthetic peptides, antibodies against them and their use
TR199900666T2 (xx) �nsan paratormonu ile ilgili peptidlere kar�� antikor.
HUP9901186A2 (hu) Peptid-és adjuvánsalapú gyógyszerkészítmény immunmodulációra
KR970707153A (ko) 카텝신 02 프로테아제(cathepsin 02 protease)
TR200601231T2 (tr) Alzheimer hastalığı sekretazı.
ES2065911T3 (es) Produccion de proteinas en formas activas.
FR2669338B1 (es)
SE8703225D0 (sv) Monoclonal antibodies and peptides useful in treating and diagnosing hiv infections
DE69132581D1 (de) Verbesserte chimäre toxine
ATE410514T1 (de) Calciumbindende rekombinante antikörper gegen protein c
SE8204811D0 (sv) Dna fragment comprising a signal sequence
ES2082132T3 (es) Composicion que contiene al menos dos anticuerpos distintos o fragmentos de ellos.
TR200002611T2 (tr) Beta-lipotropin ve kullanımları
ATE293163T1 (de) Cyclin e spezifische konstrukte und komplexe
TR200003184T2 (tr) ''İnsülin benzeri büyüme faktörünü bağlayan proteinin selektif klivajını yapabilen yeni serin proteazı''

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 517829

Country of ref document: ES